In terms of Petracker in the launch announcement a few weeks ago, they said from the initial 3 distribution deals they are expecting first year sales of $2 million and growth there after. They also say they expect to announce first sales to additional distribution partners in coming weeks with multiple deals in the USA, Europe and Asia Pacific in the final stages of negotiation and documentation.
They clearly see the revenue potential as significant and near term. We can make of that what we will, however if they are correct and with some decent revenue growth that can reasonably be expected from Sentia and possibly some early revenue associated with the FDA approval of Xpericia, real revenue traction may occur in a nearer term timeframe.
UBI Price at posting:
23.0¢ Sentiment: Buy Disclosure: Held
(20min delay)